Back to resultsA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2)
Primary Purpose
Chronic Migraine in Children
Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Eptinezumab
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Migraine in Children
Eligibility Criteria
Inclusion Criteria:
- The participant has a diagnosis of migraine (with or without aura) as defined by International Classification of Headache Disorders 3 (ICHD-3) guidelines with history of chronic migraine, of at least 6 months prior to the screening visit.
- During the 28-day screening period, the participant must adequately complete the headache eDiary on at least 24 of the 28 days following the screening visit.
- During the 28-day screening period, the participant must have ≥15 to ≤26 headache days, of which at least 8 are migraine days as documented in the eDiary.
Exclusion Criteria:
- The participant has previously been enrolled in this study and exposed to eptinezumab.
- The participant has been exposed to any monoclonal antibody treatment (including exposure in a study) <6 months prior to the screening visit.
- The participant has been exposed to another calcitonin gene-related peptide (CGRP) antibody (including exposure in a study investigating a CGRP antibody) <6 months prior to the screening visit.
- The participant has a history or diagnosis of complicated migraine (ICHD-3 version, 2018), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, ophthalmoplegic migraine, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
Sites / Locations
- Ki Health Partners LLC DBA New England Institute for Clinical ResearchRecruiting
- Children's National Medical CenterRecruiting
- NW FL Clinical Research Group, LLCRecruiting
- A G A Clinical Trials - HyperCore - PPDSRecruiting
- Axcess Medical ResearchRecruiting
- University of South FloridaRecruiting
- University of Kentucky HealthCare (UKHC) Kentucky ClinicRecruiting
- University of MarylandRecruiting
- Michigan Head Pain and Neurological InstituteRecruiting
- Michigan State University - Department of NeurologyRecruiting
- Spectrum Health HospitalsRecruiting
- Dent Neurosciences Research Center IncorporatedRecruiting
- North Suffolk Neurology-CommackRecruiting
- OnSite Clinical Solutions, LLC - Charlotte - ClinEdge - PPDSRecruiting
- The University of Oklahoma Health Sciences Center
- Road Runner Research LtdRecruiting
- Children's Specialty GroupRecruiting
- Mary Bridge Children's Hospital
- Marshall University Medical CenterRecruiting
- Hospital Privado de La ComunidadRecruiting
- Clinica Privada IndependenciaRecruiting
- Hospital Italiano de Buenos Aires
- Expertia S.A- Mautalen Salud e InvestigacionRecruiting
- Hospital Britanico de Buenos AiresRecruiting
- Sanatorio Allende S.A.Recruiting
- Hospital de Niños de La Santisima TrinidadRecruiting
- Instituto Médico Río CuartoRecruiting
- INECO Neurociencias OronoRecruiting
- Centro de Investigaciones Médicas TucumanRecruiting
- Medical Arts Health Research Group - PentictonRecruiting
- Vancouver Island Health AuthorityRecruiting
- The Kids ClinicRecruiting
- Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e Cura a Carattere ScientificoRecruiting
- Ospedale San Raffaele S.r.l. - INCIPIT - PINRecruiting
- Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3Recruiting
- Fondazione Istituto Neurologico Mondino IRCCSRecruiting
- Azienda Ospedaliero Universitaria Consorziale Policlinico di BariRecruiting
- AO Brotzu - Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza - INCIPIT - PINRecruiting
- Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PINRecruiting
- Centro de Investigacion Medico Biologica y de Terapia Avanzada S.C.Recruiting
- Neurociencias Estudios Clinicos S.C.Recruiting
- Instituto de Investigationes Clinicas para la Salud A.C.Recruiting
- Clinical Research InstituteRecruiting
- Hospital Garcia de OrtaRecruiting
- Hospital Pediatrico de CoimbraRecruiting
- Centro Hospitalar de São João, E.P.E.Recruiting
- Childrens University HospitalRecruiting
- University Clinical Center KragujevacRecruiting
- Children and Youth Health Care Institute of VojvodinaRecruiting
- Clinical Centre of VojvodinaRecruiting
- Hospital Universitario Vall d'Hebron - PPDSRecruiting
- Instituto de Investigaciones del Sueño
- Hospital Universitario Virgen del Rocio - PPDSRecruiting
- Hospital Universitari i Politecnic La Fe de ValenciaRecruiting
- Royal Devon and Exeter Hospital NHS TrustRecruiting
- Queen Elizabeth University Hospital - PPDSRecruiting
- James Paget University Hospitals NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Eptinezumab 300 mg
Eptinezumab 100 mg
Placebo
Arm Description
Participants will receive a single IV infusion of eptinezumab 300 mg (weight adjusted).
Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).
Participants will receive a single IV infusion of placebo matching to eptinezumab.
Outcomes
Primary Outcome Measures
Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12
Secondary Outcome Measures
Percentage of Participants With 50% Reduction From Baseline in MMDs Averaged Over Weeks 1-12
Percentage of Participants With Migraine on the Day After Dosing (Day 1)
Change From Baseline in MMDs With Use of Acute Medication Averaged Over Weeks 1-12
Percentage of Participants With 75% Reduction From Baseline in MMDs Averaged Over Weeks 1-12
Percentage of Participants With 75% Reduction From Baseline in MMDs Averaged Over Weeks 1-4
Percentage of Participants With 50% Reduction From Baseline in MMDs Averaged Over Weeks 1-4
Change From Baseline in Monthly Headache Days Averaged Over Weeks 1-12
Change From Baseline in Rate of Migraines With Severe Pain Intensity Averaged Over Weeks 1-12
Change From Baseline in Days With Use of Acute Medication Averaged Over Weeks 1-12
Change From Baseline in Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS) Score Averaged Over Weeks 1-12
Free Eptinezumab Plasma Concentration
Number of Participants With Specific Anti-Eptinezumab Antibodies (Anti-Drug Antibodies [ADA])
Number of Participants With Specific Anti-Eptinezumab Antibodies for Neutralizing Activity (NAb)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04965675
Brief Title
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Acronym
PROSPECT-2
Official Title
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2021 (Actual)
Primary Completion Date
December 3, 2023 (Anticipated)
Study Completion Date
January 28, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
H. Lundbeck A/S
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Detailed Description
The study includes a single intravenous (IV) infusion of the study drug and consists of a screening period (4 weeks), a double-blind, placebo-controlled period (12 weeks), and a safety follow-up period (8 weeks). Participants confirmed eligible will be randomized (1:1:1) to receive a single IV infusion of either eptinezumab 300 milligrams (mg) dose (weight adjusted; targeting adult exposure after 300 mg IV), eptinezumab 100 mg (weight adjusted; targeting adult exposure after 100 mg IV), or placebo at randomization visit. The doses will be adjusted for the participant's body weight.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Migraine in Children
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
285 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Eptinezumab 300 mg
Arm Type
Experimental
Arm Description
Participants will receive a single IV infusion of eptinezumab 300 mg (weight adjusted).
Arm Title
Eptinezumab 100 mg
Arm Type
Experimental
Arm Description
Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive a single IV infusion of placebo matching to eptinezumab.
Intervention Type
Drug
Intervention Name(s)
Eptinezumab
Other Intervention Name(s)
Vyepti
Intervention Description
Eptinezumab will be administered per dose and schedule specified in the arm.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matching to eptinezumab will be administered per schedule specified in the arm.
Primary Outcome Measure Information:
Title
Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12
Time Frame
Baseline, Weeks 1-12
Secondary Outcome Measure Information:
Title
Percentage of Participants With 50% Reduction From Baseline in MMDs Averaged Over Weeks 1-12
Time Frame
Baseline up to Weeks 1-12
Title
Percentage of Participants With Migraine on the Day After Dosing (Day 1)
Time Frame
Day 1
Title
Change From Baseline in MMDs With Use of Acute Medication Averaged Over Weeks 1-12
Time Frame
Baseline, Weeks 1-12
Title
Percentage of Participants With 75% Reduction From Baseline in MMDs Averaged Over Weeks 1-12
Time Frame
Baseline up to Weeks 1-12
Title
Percentage of Participants With 75% Reduction From Baseline in MMDs Averaged Over Weeks 1-4
Time Frame
Baseline up to Weeks 1-4
Title
Percentage of Participants With 50% Reduction From Baseline in MMDs Averaged Over Weeks 1-4
Time Frame
Baseline up to Weeks 1-4
Title
Change From Baseline in Monthly Headache Days Averaged Over Weeks 1-12
Time Frame
Baseline, Weeks 1-12
Title
Change From Baseline in Rate of Migraines With Severe Pain Intensity Averaged Over Weeks 1-12
Time Frame
Baseline, Weeks 1-12
Title
Change From Baseline in Days With Use of Acute Medication Averaged Over Weeks 1-12
Time Frame
Baseline, Weeks 1-12
Title
Change From Baseline in Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS) Score Averaged Over Weeks 1-12
Time Frame
Baseline, Weeks 1-12
Title
Free Eptinezumab Plasma Concentration
Time Frame
Randomization ( pre-dose [Week 0]), Week 8, Week 12, and safety follow up visit (Week 20)
Title
Number of Participants With Specific Anti-Eptinezumab Antibodies (Anti-Drug Antibodies [ADA])
Time Frame
From randomization (Week 0) up to Week 20
Title
Number of Participants With Specific Anti-Eptinezumab Antibodies for Neutralizing Activity (NAb)
Time Frame
From randomization (Week 0) up to Week 20
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The participant has a diagnosis of migraine (with or without aura) as defined by International Classification of Headache Disorders 3 (ICHD-3) guidelines with history of chronic migraine, of at least 6 months prior to the screening visit.
During the 28-day screening period, the participant must adequately complete the headache eDiary on at least 23 of the 28 days following the screening visit.
During the 28-day screening period, the participant must have ≥15 to ≤26 headache days, of which at least 8 are migraine days as documented in the eDiary.
Exclusion Criteria:
The participant has previously been randomised in this study and exposed to eptinezumab.
The participant has been exposed to any monoclonal antibody treatment (including exposure in a study) <6 months prior to the screening visit.
The participant has been exposed to another calcitonin gene-related peptide (CGRP) antibody (including exposure in a study investigating a CGRP antibody) <6 months prior to the screening visit.
The participant has a history or diagnosis of complicated migraine (ICHD-3 version, 2018), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, ophthalmoplegic migraine, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration; for example >60 minutes).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Email contact via H. Lundbeck A/S
Phone
+45 36301311
Email
LundbeckClinicalTrials@Lundbeck.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Email contact via H. Lundbeck A/S
Organizational Affiliation
H. Lundbeck A/S
Official's Role
Study Director
Facility Information:
Facility Name
Ki Health Partners LLC DBA New England Institute for Clinical Research
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905-1206
Country
United States
Individual Site Status
Recruiting
Facility Name
Children's National Medical Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010-2916
Country
United States
Individual Site Status
Recruiting
Facility Name
NW FL Clinical Research Group, LLC
City
Gulf Breeze
State/Province
Florida
ZIP/Postal Code
32561-4458
Country
United States
Individual Site Status
Recruiting
Facility Name
A G A Clinical Trials - HyperCore - PPDS
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012-3407
Country
United States
Individual Site Status
Recruiting
Facility Name
Axcess Medical Research
City
Loxahatchee Groves
State/Province
Florida
ZIP/Postal Code
33470-9272
Country
United States
Individual Site Status
Recruiting
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612-6601
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Kentucky HealthCare (UKHC) Kentucky Clinic
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40508-1683
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Maryland
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Individual Site Status
Recruiting
Facility Name
Michigan Head Pain and Neurological Institute
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48104-5131
Country
United States
Individual Site Status
Recruiting
Facility Name
Michigan State University - Department of Neurology
City
East Lansing
State/Province
Michigan
ZIP/Postal Code
48824-7015
Country
United States
Individual Site Status
Recruiting
Facility Name
Spectrum Health Hospitals
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503-2560
Country
United States
Individual Site Status
Recruiting
Facility Name
Dent Neurosciences Research Center Incorporated
City
Amherst
State/Province
New York
ZIP/Postal Code
14226-1746
Country
United States
Individual Site Status
Recruiting
Facility Name
North Suffolk Neurology-Commack
City
Commack
State/Province
New York
ZIP/Postal Code
11725-2808
Country
United States
Individual Site Status
Recruiting
Facility Name
OnSite Clinical Solutions, LLC - Charlotte - ClinEdge - PPDS
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28211-5027
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Oklahoma Health Sciences Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Completed
Facility Name
Road Runner Research Ltd
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78249-3539
Country
United States
Individual Site Status
Recruiting
Facility Name
Children's Specialty Group
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510-1021
Country
United States
Individual Site Status
Recruiting
Facility Name
Mary Bridge Children's Hospital
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405-4048
Country
United States
Individual Site Status
Completed
Facility Name
Marshall University Medical Center
City
Huntington
State/Province
West Virginia
ZIP/Postal Code
25701-3656
Country
United States
Individual Site Status
Recruiting
Facility Name
Hospital Privado de La Comunidad
City
Mar Del Plata
State/Province
Buenos Aires
ZIP/Postal Code
7603
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Clinica Privada Independencia
City
Munro
State/Province
Buenos Aires
ZIP/Postal Code
1605
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Hospital Italiano de Buenos Aires
City
Ciudad Autonoma Buenos Aires
State/Province
Ciudad Autonoma De BuenosAires
ZIP/Postal Code
C1181ACH
Country
Argentina
Individual Site Status
Completed
Facility Name
Expertia S.A- Mautalen Salud e Investigacion
City
Ciudad Autonoma de Buenos Aires
State/Province
Ciudad Autonoma De BuenosAires
ZIP/Postal Code
C1128AAF
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Hospital Britanico de Buenos Aires
City
Ciudad Autonoma de Buenos Aires
State/Province
Ciudad Autonoma De BuenosAires
ZIP/Postal Code
C1280
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Sanatorio Allende S.A.
City
Ciudad De Cordoba
State/Province
Cordoba
ZIP/Postal Code
X5000JHGQ
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Hospital de Niños de La Santisima Trinidad
City
Cordoba-Barrio Crisol
State/Province
Cordoba
ZIP/Postal Code
X5014AKM
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Instituto Médico Río Cuarto
City
Río Cuarto
State/Province
Cordoba
ZIP/Postal Code
5800
Country
Argentina
Individual Site Status
Recruiting
Facility Name
INECO Neurociencias Orono
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000DTP
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Centro de Investigaciones Médicas Tucuman
City
San Miguel de Tucuman
State/Province
Tucuman
ZIP/Postal Code
T4000AXL
Country
Argentina
Individual Site Status
Recruiting
Facility Name
Medical Arts Health Research Group - Penticton
City
Penticton
State/Province
British Columbia
ZIP/Postal Code
V2A 5L5
Country
Canada
Individual Site Status
Recruiting
Facility Name
Vancouver Island Health Authority
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V8R 1J8
Country
Canada
Individual Site Status
Recruiting
Facility Name
The Kids Clinic
City
Ajax
State/Province
Ontario
ZIP/Postal Code
L1Z 0M1
Country
Canada
Individual Site Status
Recruiting
Facility Name
Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico
City
Genova
State/Province
Liguria
ZIP/Postal Code
16147
Country
Italy
Individual Site Status
Recruiting
Facility Name
Ospedale San Raffaele S.r.l. - INCIPIT - PIN
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Recruiting
Facility Name
Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Name
Fondazione Istituto Neurologico Mondino IRCCS
City
Pavia
State/Province
Lombardia
ZIP/Postal Code
27100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
City
Bari
State/Province
Puglia
ZIP/Postal Code
70124
Country
Italy
Individual Site Status
Recruiting
Facility Name
AO Brotzu - Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza - INCIPIT - PIN
City
Cagliari
State/Province
Sardegna
ZIP/Postal Code
09121
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN
City
Firenze
State/Province
Toscana
ZIP/Postal Code
50139
Country
Italy
Individual Site Status
Recruiting
Facility Name
Centro de Investigacion Medico Biologica y de Terapia Avanzada S.C.
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44700
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Neurociencias Estudios Clinicos S.C.
City
Culiacan Sinaloa
ZIP/Postal Code
80020
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Instituto de Investigationes Clinicas para la Salud A.C.
City
Durango
ZIP/Postal Code
34000
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Clinical Research Institute
City
Tepetlacalco
ZIP/Postal Code
54055
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Hospital Garcia de Orta
City
Almada
State/Province
Setúbal
ZIP/Postal Code
2805-267
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Hospital Pediatrico de Coimbra
City
Coimbra
ZIP/Postal Code
3000-602
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Centro Hospitalar de São João, E.P.E.
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Childrens University Hospital
City
Beograd
State/Province
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
University Clinical Center Kragujevac
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Children and Youth Health Care Institute of Vojvodina
City
Novi Sad
ZIP/Postal Code
21 000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Clinical Centre of Vojvodina
City
Novi Sad
ZIP/Postal Code
21 000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Vall d'Hebron - PPDS
City
Barcelona
ZIP/Postal Code
8025
Country
Spain
Individual Site Status
Recruiting
Facility Name
Instituto de Investigaciones del Sueño
City
Madrid
ZIP/Postal Code
28036
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital Universitario Virgen del Rocio - PPDS
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari i Politecnic La Fe de Valencia
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Name
Royal Devon and Exeter Hospital NHS Trust
City
Exeter
State/Province
Devon
ZIP/Postal Code
EX2 5DW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Queen Elizabeth University Hospital - PPDS
City
Glasgow
State/Province
Lanarkshire
ZIP/Postal Code
G51 4TF
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
James Paget University Hospitals NHS Foundation Trust
City
Great Yarmouth
State/Province
Norfolk
ZIP/Postal Code
NR31 6LA
Country
United Kingdom
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
We'll reach out to this number within 24 hrs